Business description
Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.
Management board & Supervisory board
| CEO |
| Thomas Meier |
| Management board |
| Alain Schaffter, Dr. Anne-Kathrin Stoller, Dr. Günther Loidl, Torsten Wohr |
| Supervisory board |
| Dr. Kuno Sommer, Dr. Alex Fässler, Dr. h.c. Peter Grogg, Dr. Steffen Lang, Nicole Grogg Hötzer, Prof. Dr. Helma Wennemers |
Company data
| Name: |
Bachem Holding AG |
| Address: |
Hauptstraße 144,CH-4416 Bubendorf |
| Phone: |
+41-58-595-2020 |
| Fax: |
+41-58-595-2040 |
| E-mail: |
sales.ch@bachem.com
|
| Internet: |
www.bachem.com |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
38.00% |
| IPO date: |
1998-07-22 |
Investor relations
| Name: |
Daniel Grotzky |
| IR phone: |
+41-58-595-2021 |
| IR Fax: |
+41-58-595-2043 |
| IR e-mail: |
ir@bachem.com
|
